The Alzheimer's Screening and Prevention Act would expand Medicare coverage to include blood-based screening tests that detect early-stage Alzheimer's disease and related dementias. The bill amends Medicare rules to cover FDA-approved tests starting January 1, 2028, including blood tests that analyze genetic material, proteins, and other biomarkers. This would allow Medicare beneficiaries to access these early detection tests as a covered benefit, potentially helping identify the disease before significant symptoms appear. The legislation applies to blood-based tests and comparable screening methods approved by the FDA, and Medicare would pay for these services under the same framework as other covered diagnostic tests. No specific funding amount is mentioned in the bill; instead, it establishes the coverage requirement, with actual costs to be determined as the tests are utilized by Medicare beneficiaries.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.